Partial Seizure - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 78 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Partial Seizure - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Partial Seizure - Pipeline Review, H2 2014', provides an overview of the Partial Seizure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Partial Seizure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Partial Seizure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Partial Seizure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Partial Seizure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Partial Seizure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Partial Seizure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Partial Seizure Overview 7
Therapeutics Development 8
Pipeline Products for Partial Seizure - Overview 8
Pipeline Products for Partial Seizure - Comparative Analysis 9
Partial Seizure - Therapeutics under Development by Companies 10
Partial Seizure - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Partial Seizure - Products under Development by Companies 14
Partial Seizure - Companies Involved in Therapeutics Development 15
Novartis AG 15
Eisai Co., Ltd. 16
Pfizer Inc. 17
UCB S.A. 18
Marinus Pharmaceuticals, Inc. 19
SciFluor Life Sciences, LLC 20
SK Biopharmaceuticals Co., Ltd. 21
Partial Seizure - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
levetiracetam - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
lacosamide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
brivaracetam - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
perampanel - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
carisbamate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pregabalin CR - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Remegal - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ganaxolone - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
YKP-3089 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
selurampanel - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SF-0034 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Partial Seizure - Recent Pipeline Updates 53
Partial Seizure - Dormant Projects 65
Partial Seizure - Discontinued Products 66
Partial Seizure - Product Development Milestones 67
Featured News & Press Releases 67
May 01, 2014: Kyowa Hakko Kirin Announces Launch Of New Formulation Of Topina, an Antiepileptic Agent 67
Apr 29, 2014: Sunovion Pharmaceuticals Presents Data on Aptiom (eslicarbazepine acetate) at 66th American Academy of Neurology Annual Meeting 67
Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of Neurology's 66th Annual Meeting 69
Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional Benefit Assessment 69
Jan 22, 2014: Zonegran Reimbursed in Switzerland as Monotherapy Treatment for Adults With Newly Diagnosed Partial Epilepsy 70
Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S. 71
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA (perampanel) CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older 72
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older 73
Dec 09, 2013: Sunovion Pharmaceuticals Presents Phase 3 Pooled Analysis Of Once-Daily Aptiom As Adjunctive Treatment For Partial-Onset Seizures 74
Dec 09, 2013: Sunovion Pharmaceuticals Presents Positive Results From Two Phase 3 Studies of Once-Daily Aptiom as Monotherapy Treatment for Partial-Onset Seizures 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
Number of Products under Development for Partial Seizure, H2 2014 8
Number of Products under Development for Partial Seizure - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Partial Seizure - Pipeline by Novartis AG, H2 2014 15
Partial Seizure - Pipeline by Eisai Co., Ltd., H2 2014 16
Partial Seizure - Pipeline by Pfizer Inc., H2 2014 17
Partial Seizure - Pipeline by UCB S.A., H2 2014 18
Partial Seizure - Pipeline by Marinus Pharmaceuticals, Inc., H2 2014 19
Partial Seizure - Pipeline by SciFluor Life Sciences, LLC, H2 2014 20
Partial Seizure - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Partial Seizure Therapeutics - Recent Pipeline Updates, H2 2014 53
Partial Seizure - Dormant Projects, H2 2014 65
Partial Seizure - Discontinued Products, H2 2014 66